Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces hi...
For the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis syndrome. Verteporfin can also be used to destroy tumors.
Manhattan Eye, Ear & Throat Hospital, New York, New York, United States
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Midwest Children's Cancer Center at Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.